2020

Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits

Fayyaz, Anam

Elsevier BV

Tieteelliset aikakauslehtiartikkelit
© 2020 The Authors
CC BY http://creativecommons.org/licenses/by/4.0/
http://dx.doi.org/10.1016/j.ejps.2020.105553

https://erepo.uef.fi/handle/123456789/24403
Downloaded from University of Eastern Finland's eRepository
Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits

Anam Fayyaz\textsuperscript{a,b}, Veli-Pekka Ranta\textsuperscript{b}, Elisa Toropainen\textsuperscript{b}, Kati-Sisko Vellonen\textsuperscript{b}, Annika Valtari\textsuperscript{b}, Jooseppi Puranen\textsuperscript{b}, Marika Ruponen\textsuperscript{b}, Iain Gardner\textsuperscript{a}, Arto Urtti\textsuperscript{b,c,d}, Masoud Jamei\textsuperscript{a}, Eva M. del Amo\textsuperscript{b,⁎}

\textsuperscript{a} Certara UK, Simcyp Division, Level 2-Acero, 1 Concourse Way, Sheffield, S1 2BJ, United Kingdom

\textsuperscript{b} University of Eastern Finland, School of Pharmacy, Biopharmaceutics, Yliopistonranta 1, Kuopio 70210, Finland

\textsuperscript{c} University of Helsinki, Faculty of Pharmacy, Drug Research Program, Yliopistonkatu 3, Helsinki 00014, Finland

\textsuperscript{d} Saint-Petersburg State University, Institute of Chemistry, Universitetskiy Prospekt, 26, Petergoff 198504, Russian Federation

\textbf{ARTICLE INFO}

\textbf{Keywords:}

Timolol
Betaxolol
Atenolol
Ocular pharmacokinetics
Rabbit
Eye drop
Ocular bioavailability

\textbf{ABSTRACT}

Ocular bioavailability after eye drops administration is an important, but rarely determined, pharmacokinetic parameter. In this study, we measured the pharmacokinetics of a cocktail of three beta blockers after their topical administration into the albino rabbit eye. Samples from aqueous humour were analysed with LC-MS/MS. The pharmacokinetic parameters were estimated using compartmental and non-compartmental analyses. The ocular bioavailability was covering broad range of values: atenolol (0.07 %), timolol (1.22%, 1.51%) and betaxolol (3.82%, 4.31%). Absolute ocular bioavailability presented a positive trend with lipophilicity and the values showed approximately 60-fold range. The generated data enhances our understanding for ocular pharmacokinetics of drugs and may be utilized in pharmacokinetic model building in ophthalmic drug development.

1. Introduction

Topical administration is currently the most common route for the treatment of diseases affecting the anterior part of the eye. Ocular bioavailability after topical administration is stated to be less than 10 %, but bioavailability has been determined only for four compounds in rabbits and not at all in humans. Several pre-corneal factors, such as the drainage of excess fluid, normal tear turnover and systemic absorption through conjunctiva remove the drug from the ocular surface decreasing the drug absorption into intraocular tissues (Himmelstein et al., 1978; Lee and Robinson, 1979). Flow of drug solution into the nasolacrimal duct leads to further systemic absorption from the nasal mucosa and gastrointestinal tract (Himmelstein et al., 1978; Lee and Robinson, 1979; Urtti and Salminen, 1993).

The main ocular absorption routes after topical administration are across the cornea and conjunctiva (Fig. 1). After corneal absorption the drug permeates into the aqueous humour and further into the iris and ciliary body followed by elimination to the systemic circulation. Drug may also be eliminated by aqueous humour turnover into the trabecular meshwork and Schlemm's canal or distribute into the lens. Transfer of drug towards the vitreous humour is hindered by the aqueous humour flow in the posterior-to-anterior direction (Maurice and Mishima, 1984). Drug may also absorb into the eye across the conjunctiva and sclera and then distribute further into the iris and ciliary body (Ahmed et al., 1987; Ahmed and Patton, 1985). Most of conjunctival drug permeation leads to systemic circulation instead of intraocular distribution.

The corneal permeation is the most important ocular absorption route for lipophilic drugs (Doane et al., 1978; Schoenwald, 1987). The corneal epithelium is the main penetration barrier in the cornea (Lach et al., 1983; Schoenwald, 1987; Schoenwald, 1990; Schoenwald and Huang, 1983). Transconjunctival drug absorption contributes very little to drug concentrations in the aqueous humour (Ahmed et al., 1987; Ahmed and Patton, 1985) which is the main site in the assessment of topical ocular bioavailability.

The absolute ocular bioavailability is the ratio of the dose-absorbed into the eye to the dose-applied.
normalized areas under the concentration curve (AUC) in aqueous humour after topical and intracameral administration, respectively. In the latter case, the drug is directly injected into the anterior chamber and this situation represents 100% bioavailability.

In the present study we determined the topical pharmacokinetics for three anti-glaucoma drugs, atenolol, timolol, and betaxolol that represent a range of lipophilicity values (Fig. 2). These beta-blockers were applied topically as a cocktail on rabbit eyes, aqueous humour drug concentrations were quantified and pharmacokinetic parameters were determined including absolute ocular bioavailability (with intracameral pharmacokinetic data from our previous study (Fayyaz et al., 2019)).

2. Material and Method

2.1. Animal experiments

Animals - Sixteen male albino New Zealand rabbits, age 3–6 months and weight 2.8–3.2 kg, were used in the experiments. The animals were housed in a temperature and humidity-controlled environment with a 12/12 light/dark cycle. The animals were individually housed and fed a normal diet. All rabbits underwent an ocular examination before being accepted into experiments. Animals were handled in accordance with the statement of the Animals in Research Committee of the ARVO (Association for Research in Vision and Ophthalmology, Rockville, Maryland, USA) and all animal experiments were approved by the national Animal Experiment Board of Finland.

Topical application of the beta-blocker cocktail was performed followed by a collection of a single aqueous humour sample from each animal. The sampling times were 5, 10, 20, 30, 60, 120, 180 and 240 min, and the number of eyes at each time point were four (n = 4). The cocktail containing 20 mM atenolol (USP reference standard, Sigma), 10 mM betaxolol hydrochloride (USP reference standard, Sigma) and 10 mM timolol maleate (USP reference standard, Sigma) in phosphate-buffered saline (DPBS, Thermofisher Scientific) (pH adjusted to 7.4; 322 mOsm/kg) was administered onto the upper cornea-scleral limbus of both eyes (25 µL/eye) in each rabbit. The animals were sacrificed by injecting into the marginal ear vein a lethal dose of pentobarbital (Mebunat vet 60 mg/mL; Orion Pharma, Finland) and aqueous humour was aspirated from anterior chamber. All samples were cooled on ice following storage at -80 °C until analysis.

2.2. Analysis of aqueous humour samples

Standards (0.1 – 5000 nM) were prepared from the beta blocker mixture in PBS and diluted with a solution containing 20% porcine aqueous humour and 80% PBS. Atenolol-d7 (Toronto Research Chemicals, Canada), betaxolol-d5 (Toronto Research Chemicals, Canada) and Rac timolol-d5 Maleate (Toronto Research Chemicals, Canada) were used as internal standards (ISTDs). The 1 mg/mL stock solutions were first prepared in DMSO and then diluted to ISTD solution containing 50 ng/mL atenolol-d7, 5 ng/mL betaxolol-d5, 5 ng/mL rac timolol-d5 maleate and 1% formic acid in acetonitrile.

Equal volumes (50 µL) of standard solutions and ISTD solution were mixed by vortexing for 10 sec. After 15 min precipitation step the standards were centrifuged (5 min, +4°C, 13000 rpm) and supernatant was collected for LC-MS analysis. Quality controls (2.5, 25, 250 and 1500 nM) in triplicates were prepared in similar manner. Aqueous humour samples were first diluted 1:5 with PBS and then ISTD solution
was added. Thereafter, the procedure was similar to the handling of standards. The standards, samples and quality controls were analysed with LC-MS/MS (Agilent 1290 liquid chromatograph and Agilent 6495 triple quadruple mass spectrometer, Agilent Technologies Inc., USA) using protocol described earlier (Fayyaz et al., 2019).

The calibration curve was prepared as duplicate and calculated as a mean of two injections using 9–11 concentration levels of total 14 levels. Calibration curves had 85 - 115 % mean accuracies. QC samples were 90 - 110% of the nominal concentrations with imprecision below 10%.

2.3. Pharmacokinetic analysis

Compartmental analysis was performed using Phoenix WinNonlin (build 8.1, Certara L.P.). Mean concentration data was analysed using one- and two-compartment models with first-order absorption kinetics. Akaike's information criterion and visual inspection of the plot of observed and predicted concentrations versus time were used to select the best compartmental model. Curve fitting was performed using three different weighting schemes: uniform, 1/predicted concentration (1/Yhat) and 1/(predicted concentration)^2 (1/Yhat^2). Coefficient of variation (CV%) of estimated parameters and residual plots were utilized for choosing the best weighting scheme within the same compartmental model. AUC from time zero to infinity (AUC_{inf,Top}), the maximal concentration (C_{max,Top}), time at the maximal concentration (t_{max,Top}) and elimination half-life (t_{1/2,Top}) were obtained following topical application of the three drugs. Non-compartmental analysis was also performed using mean concentrations and the linear trapezoidal rule (Supplementary data Table S3).

Aqueous humour bioavailability for the three beta-blockers was calculated according to Eq. 1:

\[
\text{Bioavailability} = \frac{AUC_{inf,Top} \times \text{Dose}_{IC}}{AUC_{inf,IC} \times \text{Dose}_{top}}
\]  

where Top and IC refer to topical and intracameral administration, respectively. Data for IC administration were taken from our previous study (Fayyaz et al., 2019).

3. Results

3.1. Topical pharmacokinetic parameters

The mean aqueous humour concentration data was fitted for the three beta blockers. One-compartment model was the best structural model, using the 1/Yhat\(^2\) weighting model for all three drugs. The final model estimated concentrations are presented in Fig. 3 together with the observed data. The more lipophilic compounds betaxolol and timolol achieved higher aqueous humour concentrations than the more hydrophilic compound atenolol. Five measured aqueous humour concentrations across the three drugs were excluded from the pharmacokinetics analysis since they were considered to be outliers (Supplementary data Table S1). The pharmacokinetic parameters estimated from the compartmental analysis are listed in Table 1.

The AUC_{inf,Top} of betaxolol was 12 and 2 times higher than the dose-normalized values of atenolol and timolol, respectively and similar trends are seen for C_{max,Top} (Table 1). The half-life of atenolol in the aqueous humour was 3–5 times longer than the half-lives of timolol and betaxolol.

3.2. Absolute topical bioavailabilities

The dose-normalized comparison of the concentration profiles of the three beta-blockers after topical and intracameral administration in rabbit eye (Fayyaz et al., 2019) is presented in Fig. 4.

Drug bioavailability values in aqueous humour from our topical pharmacokinetic study and the previous intracameral study (Fayyaz et al., 2019) are presented in Table 2. The order of bioavailabilities is betaxolol > timolol > atenolol based on both compartmental and non-compartmental analyses. The results show a substantial 55–62-fold difference between the bioavailability of betaxolol (3.82%, 4.31%) and atenolol (0.07%).

4. Discussion

A cocktail approach was used to determine the ocular exposure of three drugs after topical administration. This approach reduces the number of animals needed and reduces variability arising due to interindividual differences and analytical factors. Previously, we have used the same approach to investigate the intracameral pharmacokinetics of the same drug set in the rabbit eye (Fayyaz et al., 2019). The combination of both studies allows us to determine the absolute bioavailability in aqueous humour for betaxolol, timolol and atenolol. Both compartmental analysis and non-compartmental analysis were carried out and yielded similar bioavailability values showing robust results. Ocular bioavailability is typically determined for aqueous humour, even though ciliary body is the target tissue for beta blocker antiglaucoma drugs. The reason is that bioavailability calculation requires a direct injection into the investigated tissue for the determination of the drug clearance from the tissue. This is not feasible for iris-ciliary body, while it is possible for aqueous humour after intracameral injection.

Bioavailability is critically important parameter that provides useful information on the ocular exposure of different drugs and drugs in different formulations. Bioavailability shows the drug fraction absorbed in aqueous humour, while the concentration curves in the aqueous humour after topical administration are not only affected by absorption but also by the clearance from the aqueous humour (CL_{HC} in Table 2, Fig. 4). Unfortunately, there are only a few studies that report pharmacokinetics for both topical and intracameral administration of ophthalmic drugs (Ling and Combs, 1987; Tang-Liu et al., 1984; Yamamura et al., 1999) allowing the determination of absolute drug

![Fig. 3. Aqueous humour concentration-time profiles in rabbits after topical application of atenolol (dose = 500 nmol), timolol (dose = 250 nmol) and betaxolol (dose = 250 nmol) in a cocktail. Each circle represents the mean concentration ± standard error of the mean (n = 3–4). The best fits based on one-compartmental first-order pharmacokinetic model are represented by the dashed line.](image-url)
bioavailability to the aqueous humour. Compiling our data with these literature studies shows a wide range of ocular bioavailabilities ranging from 0.07 to 10% (Fig. 5). A positive trend of ocular bioavailability can be seen with lipophilicity (log D<sub>7.4</sub>) as lipophilic compounds tend to have a higher ocular bioavailability than more hydrophilic compounds (Fig. 5) presumably due to the higher permeability in the cornea (Kidron et al., 2010). Plotting aqueous humour pharmacokinetic parameters (C<sub>max,Top</sub>, AUC<sub>inf,Top</sub>, bioavailability) against corneal permeability or cornea/conjunctiva permeability ratios in rabbit (Wang et al., 1991) results in excellent correlation (Supplementary data Figure S3 and S4). Several studies have pointed out the importance of drug lipophilicity on corneal permeability (Chien et al., 1990; Lach et al., 1983; Rusinko et al., 2007; Schoenwald, 1987; Schoenwald and Huang, 1983; Wang et al., 1991), but it is important to note that ocular bioavailability of lipophilic drugs is also limited by their fast penetration across the conjunctiva to the systemic circulation (Ramsay et al., 2018; Wang et al., 1991). Corneal penetration may also be influenced by other factors such as drug ionization, molecular size and medium (pH, osmotic pressure, other components) (Brechue and Maren, 1993; Kidron et al., 2010; Pescina et al., 2015).

Since bioavailability data for other beta-blockers are missing, we compared the dose-normalized AUC<sub>inf,Top</sub> and C<sub>max,Top</sub> values of drug sets in which timolol was investigated (Araté et al., 1982; Huang et al., 1983; Rusinko et al., 2007; Schoenwald, 1987; Schoenwald and Huang, 1983; Wang et al., 1991) with the results from the present study.

### Table 1
Compartmental analysis of aqueous humour concentrations after topical administration of atenolol (dose = 500 nmol and dose-normalized values<sup>a</sup>), timolol (dose = 250 nmol) and betaxolol (dose = 250 nmol) in rabbits. SE = standard error of the estimates.

| Drug      | Dose (nmol) | AUC<sub>inf,Top</sub> ± SE (min*nmol/mL) | C<sub>max,Top</sub> ± SE (nmol/mL) | t<sub>max,Top</sub> ± SE (min) | t<sub>1/2,Top</sub> ± SE (min) |
|-----------|-------------|------------------------------------------|-----------------------------------|------------------------------|-------------------------------|
| Atenolol  | 500         | 48.6 ± 15.8                              | 0.22 ± 0.06                       | 31.6 ± 15.5                  | 130.4 ± 78.4                  |
|           | 250<sup>a</sup> | 24.3<sup>a</sup>                       |                                   |                              |                               |
| Timolol   | 250         | 152 ± 14                                 | 1.99 ± 0.20                       | 17.3 ± 3.7                   | 38.9 ± 2.9                    |
| Betaxolol | 250         | 280 ± 47.8                               | 4.07 ± 0.69                       | 21.9 ± 5.1                   | 27.3 ± 3.3                    |

**Fig. 4.** Aqueous humour concentration-time profiles of atenolol, timolol and betaxolol after topical and intracameral administration. The concentrations have been normalized to the dose of 250 nmol.

### Table 2
Aqueous humour bioavailability of atenolol, timolol and betaxolol using compartmental and non-compartmental analyses (CA: compartmental analysis, NCA: non-compartmental analysis).

| Drugs     | Topical administration | Intracameral administration<sup>a</sup> | Bioavailability |
|-----------|------------------------|----------------------------------------|-----------------|
|           | Dose (nmol) | AUC<sub>inf,Top</sub> ± SE (min*nmol/mL) | C<sub>max</sub> ± SE (µL/min) | Vd<sub>IC</sub> ± SE (µL) | AUC<sub>inf,IC</sub> ± SE (min*nmol/mL) | (%)  |
|-----------|-------------|------------------------------------------|----------------------|-----------------|------------------------------------------|------|
| Atenolol  | 500         | 48.6 ± 15.8                              | 6.44 ± 0.83         | 687 ± 140       | 691 ± 141                                | 545  | 0.07 | 0.07 |
| Timolol   | 250         | 152 ± 14                                 | 19.3 ± 2.66         | 937 ± 172       | 248 ± 52                                 | 199  | 1.22 | 1.51 |
| Betaxolol | 250         | 280 ± 47.8                               | 32.2 ± 4.10         | 1421 ± 236      | 146 ± 27                                 | 117  | 3.82 | 4.31 |

Vd<sub>IC</sub>: Volume of distribution after intracameral injection

C<sub>max</sub>: Clearance after intracameral injection

<sup>a</sup> Fayyaz et al., 2019

**Fig. 5.** Bioavailability versus log D<sub>7.4</sub> of ophthalmic topical drugs in rabbit eyes of six drugs i.e. atenolol, timolol and betaxolol from present study (blue diamonds, bioavailability determined using non-compartmental analysis) and ketorolac (Ling and Combs, 1987), flurbiprofen (Tang-Liu et al., 1984), timolol and tilisolol (Yamamura et al., 1999) (bioavailability determined from non-compartmental analysis) from the literature (red squares).
Figure S1) and observed higher AUC inf,Top ratio for befunolol (Yamamura et al., 1999). We compared the beta-blocker/timolol para-}


cinal draft, Writing - review & editing.


crolinal drug dosing and drug development. of the aqueous humour samples by careful sampling. In any case, these early samples have a minimal contribution to the values of $\text{AUC}_{\text{inf,Top}}$ and bioavailability, thereby they do not have any influence on our conclusions. The present data generated for atenolol, timolol and betaxolol can be used to aid further studies with these drugs. Exact values for ocular bioavailability can be useful aid in the development of new drug delivery systems (Subrizi et al., 2019).

### Conclusion

Three beta blockers were administered topically and their ocular pharmacokinetics were evaluated. Absolute bioavailability of atenolol, timolol and betaxolol was quantitated in aqueous humour. The data shows broad, about 60-fold, range of bioavailability for topical beta blocking agents. The outcomes of this study is for improved understanding on ocular pharmacokinetics and may inform ophthalmic topical drug dosing and drug development.

### CRediT authorship contribution statement

**Anam Fayyaz:** Conceptualization, Formal analysis, Writing - original draft, Writing - review & editing. **Veli-Pekka Ranta:** Methodology, Writing - review & editing. **Elsa Toropainen:** Methodology, Investigation. **Kati-Sisko Vellonen:** Methodology, Investigation. **Annika Valtari:** Methodology, Investigation. **Jooseppi Piosu:** Methodology, Investigation. **Marika Ruponen:** Project administration, Investigation, Writing - review & editing. **Iain Gardner:** Supervision, Writing - review & editing. **Arto Urtti:** Conceptualization, Supervision, Writing - review & editing, Resources. **Masoud Jamei:** Conceptualization, Supervision, Writing - review & editing, Resources. **Eva M. del Amo:** Conceptualization, Validation, Supervision, Project administration, Writing - review & editing.

### Declaration of Competing Interest

Anam Fayyaz, Masoud Jamei, and Iain Gardner are employees of Certara UK Limited, Simcyp Division.

### Acknowledgements

The work is supported by OCUTHER from European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722717, EAKR EU regional grant. Eva del Amo was additionally funded by Orion Research Foundation. Arto Urtti was supported by Russian mega grant.

Mrs. Lea Pirkkanen is acknowledged for excellent technical support and Prof. Seppo Auriola for advices regarding LC-MS/MS analytics.

### Supplementary material

Supplementary material associated with this article can be found in the online version, at doi:10.1016/j.ejps.2020.105553.

### References

Ahmed, I., Gokhale, R.D., Shah, M.V., Patton, T.F., 1987. Physicochemical determinants of drug diffusion across the conjunctiva, sclera, and cornea. J. Pharm. Sci. 76, 593–596. https://doi.org/10.1002/jps.2600760802.

Ahmed, I., Patton, T., 1985. Importance of the noncorneal absorption route in topical ophthalmic drug delivery. Invest. Ophthalmol. Vis. Sci. 26, 584–587. https://pubmed.ncbi.nlm.nih.gov/3884542/.

Arai, M., Takase, M., Sakai, Y., Ishii, Y., Yokoyama, Y., Kitagawa, M., 1982. Beta-adrenergic blockers: ocular penetration and binding to the uveal pigment. J. Ophthalmol. 26, 248–263. https://pubmed.ncbi.nlm.nih.gov/6130180/.

Breche, W.F., Maren, T.H., 1993, pH and drug ionization affects ocular pressure lowering topical carbonic anhydrase inhibitors. Invest. Ophthalmol. Vis. Sci. 34, 2581–2587. https://pubmed.ncbi.nlm.nih.gov/8325759/.

Chien, D.-S., Homy, J.J., Gluchowski, C., Tang-Liu, D.-S., 1990. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes. Curr. Eye Res. 9, 1051–1059. https://doi.org/10.1109/8213689008997579.

Doane, M.G., Jensen, A.D., Dohlan, C.H., 1978. Penetration routes of topically applied eye medications. Am. J. Ophthalmol. 85, 383–386. https://doi.org/10.1016/0002-9378(78)90027-8.

Fayyaz, A., Ranta, V.-P., Toropainen, E., Vellonen, K.-S., Ricci, G.D.A., Reinisalo, M., Heikkinen, E.M., Gardner, I., Urtti, A., Jamei, M., 2019. Ocular intracameral pharmacokinetics for a cocktail of timolol, betaxolol and atenolol in rabbits. Mol. Pharm. 17, 588–594. https://doi.org/10.1021/acs.molpharmaceut.9b01024.

Himmelstein, K.J., Guvenir, I., Patton, T.F., 1978. Preliminary pharmacokinetic model of pilocarpine uptake and distribution in the eye. J. Pharm. Sci. 67, 603–606. https://doi.org/10.1002/jps.2600670507.

Huang, H.S., Schoenwald, R.D., Lach, J.L., 1983. Corneal penetration behavior of β-blocking agents III: In Vitro–In Vivo correlations. J. Pharm. Sci. 72, 1279–1281. https://doi.org/10.1002/jps.2600721110.

Kidron, H., Vellonen, K.-S., Del Amo, E.M., Timas, A., Urtti, A., 2010. Prediction of the corneal permeability of drug-like compounds. Pharm. Res. 27, 1396–1407. https://doi.org/10.1007/s11095-010-0132-8.

Lach, J.L., Huang, H.-S., Schoenwald, R.D., 1983. Corneal penetration behavior of β-blocking agents II: assessment of barrier contributions. J. Pharm. Sci. 72, 1272–1279. https://doi.org/10.1002/jps.2600721109.

Lee, V.H.L., Robinson, J.R., 1979. Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits. J. Pharm. Sci. 68, 673–684. https://doi.org/10.1016/j.ppa.2006080606.

Ling, T.L., Combs, D.L., 1987. Ocular bioavailability and tissue distribution of [14C] ketorolac tromethamine in rabbits. J. Pharm. Sci. 76, 289–294. https://doi.org/10.1002/jps.2600760205.

Maurice, D., Mishima, S., 1984. Ocular pharmacokinetics. Pharmacology of the Eye. Springer, pp. 19–116. https://link.springer.com/chapter/10.1007/978-3-642-69222-2_2.

Ohtori, R., Sato, H., Fokuza, S., Ueda, T., Koide, R., Kanda, Y., Kiuchi, Y., Oguchi, K., 1998. Pharmacokinetics of topical β-adrenergic antagonists in rabbit aqueous humor evaluated with the microdialysis method. Exp. Eye Res. 66, 487–494. https://doi.org/10.1016/s0014-4835(97)00148-9.

Pescina, S., Govoni, P., Potenza, A., Padula, C., Santi, P., Nicolò, S., 2015. Development of a convenient ex vivo model for the study of the transcorneal permeation of drugs: histological and pharmacological evaluation. J. Pharm. Sci. 104, 63–71. https://doi.org/10.1002/jps.24231.

Ramay, E., del Amo, E.M., Toropainen, E., Tengvall-Unadike, U., Ranta, V.-P., Urtti, A., Ruponen, M., 2018. Corneal and conjunctival drug permeability: Systematic comparison and pharmacokinetic impact in the eye. Eur. J. Pharm. Sci. 119, 83–89. https://doi.org/10.1016/j.ejps.2018.03.034.

Ros, F.E., Innesec, HC, Van Zwieten, PA, 1980. The ocular penetration of beta-adrenocceptor blocking drugs-a comparative study on atenolol, sotalol, pindolol, metropolol, timolol and propranolol. Doc Ophthalmol Proc Ser 22, 313-325.

Rusinko, A., Hellberg, M.R., May, J.A., Owen, G.R., 2007. Use of MDCK cell line to predict corneal penetration of drugs. Google Patents. https://patents.google.com/patent/US20050239505A1/en.

Schmitt, C., Lotti, V., Le Douarec, J., 1981. Penetration of beta-adrenergic antagonists
into the rabbit eye after ocular instillation. Albrecht Graefes Arch. Klinische Exp. Ophthalmol. 217, 167–174. https://doi.org/10.1007/BF00411147.

Schoenwald, R., 1987. The importance of optimizing corneal penetration. Ophthalmic Drug Delivery. Springer, pp. 151–160. https://link.springer.com/chapter/10.1007/978-1-4757-4175-9_15.

Schoenwald, R.D., 1990. Ocular drug delivery. Clin. Pharm. 18, 255–269. https://doi.org/10.2165/00003088-199018040-00001.

Schoenwald, R.D., Huang, H.S., 1983. Corneal penetration behavior of β-blocking agents I: physicochemical factors. J. Pharm. Sci. 72, 1266–1272. https://doi.org/10.1002/jps.2600721108.

Subrizi, A., del Amo, E.M., Korzhikov-Vlakh, V., Tennikova, T., Ruponen, M., Urtti, A., 2019. Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties. Drug Discov. Today 24, 1446–1457. https://doi.org/10.1016/j.drudis.2019.02.001.

Tang-Liu, D.-S., Liu, S., Weinkam, R., 1984. Ocular and systemic bioavailability of ophthalmic flurbiprofen. J. Pharmacokinet. Biopharm. 12, 611–626. https://doi.org/10.1007/BF01059556.

Urtti, A., Salminen, L., 1993. Minimizing systemic absorption of topically administered ophthalmic drugs. Surv. Ophthalmol. 37, 435–456. https://doi.org/10.1016/0039-6257(93)90141-s.

Wang, W., Sasaki, H., Chien, D.-S., Lee, V.H., 1991. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: a comparison with corneal penetration. Curr. Eye Res. 10, 571–579. https://doi.org/10.3109/02713689109001766.

Yamamura, K., Sasaki, H., Nakashima, M., Ichikawa, M., Mukai, T., Nishida, K., Nakamura, J., 1999. Characterization of ocular pharmacokinetics of beta-blockers using a diffusion model after instillation. Pharm. Res. 16, 1596–1601. https://doi.org/10.1023/a:1018964823193.